Lancet 365: 1046–1053 Obstructive sleep apnea-hypopnea is widely considered to be a cardiovascular risk factor, but there are few prospective data to confirm this link or to establish whether ...

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea ... index (BMI) and apnea-hypopnea index (AHI) values ...

The two most commonly recognized types of sleep apnea are obstructive and central sleep ... cycles of reduced or stopped breathing (hypopnea) and increased breathing (hyperpnea).

The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to find out more information.

The approval of Zepbound for obstructive sleep apnea treatment is based on ... as measured by the apnea-hypopnea index (AHI). Apneas are periods when a person stops breathing and hypopneas are ...

Many major maladies have been linked to disturbed slumber caused by sleep apnea, high blood pressure, heart problems a ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

Sleep apnea affects millions of people worldwide and prevents them from getting quality sleep. It negatively affects patients ...

“This is a major step forward for patients with obstructive sleep apnea ... Zepbound reduced apnea-hypopnea index events by an average of 25 per hour after one year compared with a ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said ... was the change in the apnea hypopnea index (AHI), which tracks how ...